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Abstract
Background: The purpose of this study was to determine the rate and causes of inappropriate
rhythm detection, and to compare adequacy of ventricular arrhythmia detection by single-
-chamber and dual-chamber cardioverter-defibrillators (ICD).
Methods: We evaluated 190 patients (age 57.2 ± 11.2 years) with ICD. Follow-up: 34.3 ±
± 22 months. Dual-chamber ICD was used in 54 patients.
Results: We evaluated 2244 arrhythmia events recognized as of ventricular origin, including
ventricular tachycardia and ventricular fibrillation. 431 events (19.2%) were recognized erro-
neously and resulted in an inappropriate ICD discharge. Most cases of inappropriate therapies
(182 events, 42.23%) were due to atrial fibrillation or flutter. Overall, inappropriate arrhyth-
mia detection was found in 64 (33.6%) of 190 patients. In terms of the number of affected
patients, the most common cause of inappropriate ICD discharge was sinus tachycardia —
23 (12.1%) patients, followed by atrial fibrillation — 16 (8.4%) patients. Among 54 patients
with dual-chamber ICD, inappropriate therapy was noted in 21 (38.8%) patients, (T wave
oversensing, sinus tachycardia and atrial fibrillation etc.). No significant difference was seen
in the rate of inappropriate therapy due to a rapid supraventricular rhythm between patients
with single-chamber versus dual-chamber ICD. In contrast, patients with single-chamber ICD
more often experienced inappropriate therapy due to atrial fibrillation (155 vs. 28 patients)
and sinus tachycardia (66 vs. 9 patients).
Conclusions: Despite of introduction of new generations of ICDs, the problem of inappropriate
ICD discharge could not be eliminated. The major problem is distinction between supraven-
tricular arrhythmia and ventricular tachyarrhythmia. (Cardiol J 2009; 16, 5: 432–439)
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Introduction
Major therapeutic advances in the management
of ischemic heart disease and heart failure seen in
the last decades resulted in an increased need for
effective treatment of life-threatening cardiac ar-
rhythmia [1, 2]. Ventricular tachycardia (VT) result-
ing in hemodynamic instability and ventricular fi-
brillation (VF) are the main causes of death among
these patients [3].
In this regard, wide use of antiarrhythmic drugs
is limited by their ineffectiveness during long-term
treatment and numerous adverse effects including
proarrhythmia [4]. The effectiveness of invasive
treatment modalities, including radiofrequency (RF)
catheter ablation and antiarrhythmic cardiac sur-
gery, is also limited [5].
Implantable cardioverter-defibrillators (ICD)
are established therapeutic devices used in the
management of life-threatening cardiac arrhythmia,
and their role has been well defined in the published
guidelines [6]. Their advantage over the use of an-
tiarrhythmic drugs in patients with a history of VF
or VT, particularly in patients with reduced left
ventricular ejection fraction (LVEF < 0.35), has
been proven in major intervention trials such as the
Antiarrhythmics Versus Implantable Defibrillators
(AVID) study, the Cardiac Arrest Study Hamburg
(CASH), and the Canadian Implantable Defibrilla-
tor Study (CIDS) [7–9]. In primary prevention, the
effectiveness of ICD was documented in such clin-
ical trials as the Multicenter Unsustained Tachy-
cardia Trial (MUSTT), the Multicenter Automatic
Defibrillator Implantation Trial (MADIT), the
MADIT II study, the Sudden Cardiac Death in Heart
Failure (SCD-HeFT) study, and the COMPArisoN
of medical therapy, pacIng and defibrillatiON in
heart failure (COMPANION) study [10–14].
Major arrhythmia-related parameters that are
used by ICD to detect intracardiac signals include
the rate of ventricular and atrial rhythm (in case of
a dual-chamber ICD), sudden changes in these
rates, and the stability of the cardiac rhythm. In
addition, some devices may detect QRS width and
morphology. Therapeutic options include antitach-
ycardia pacing, defibrillation, and on-demand pac-
ing in case of bradycardia. ICD devices may also
store intracardiac electrograms recorded during an
arrhythmia event for further retrieval and evalua-
tion, thus allowing assessment of the adequacy of
therapeutic activation and discharge.
Unfortunately, despite major technological ad-
vances since introduction of the first ICD model,
these devices remain imperfect in terms of cardiac
rhythm recognition [15–17]. Adequate rhythm de-
tection is one of the major goals of ICD, and inap-
propriate arrhythmia detection, most often leading
to an inappropriate therapeutic discharge, has many
adverse consequences including impaired quality of
life, more frequent need for ICD battery replace-
ment, and proarrhythmia leading to induction of
dangerous ventricular arrhythmia. All these effects
result in more frequent hospital admissions and
increased costs of therapy [18–21].
The purpose of this study was to determine
the rate and causes of inappropriate rhythm detec-
tion, and to compare adequacy of ventricular ar-
rhythmia detection by single-chamber and dual-
-chamber ICD.
Methods
We studied 190 patients with ICD implanted in
1997 through 2004 who were followed in the ICD
outpatient clinic at the Department of Cardiology,
Pomeranian Medical University, Szczecin, Poland.
We only included patients with complete documen-
tation of each arrhythmia event (including the pro-
grammator printouts), thus allowing assessment of
the adequacy of the device therapy. The follow-up
period was from 1997 to the end of 2005.
We analyzed the following patient baseline data
at the time of first ICD implantation: age, gender,
primary cardiac diagnosis, New York Heart Asso-
ciation (NYHA) class, LVEF as determined using
echocardiography, the type of arrhythmia that was
the indication for ICD implantation, other concomitant
cardiac arrhythmia, the presence of intraventricu-
lar conduction abnormalities including left bundle
branch block (LBBB) and right bundle branch block
(RBBB), previous revascularizations, previous RF
ablation procedures, any previous pacemaker im-
plantation, and the model of implanted ICD device.
Then, we analyzed clinical data and information
from ICD programmator printouts collected during
the follow-up period. Follow-up visits were sched-
uled at one month following ICD implantation, at
3 months and every 6 months thereafter, and also
following ICD discharge events.
The study was approved by the bioethical com-
mittee and all patients gave their informed consent.
Statistical analysis
The significance of differences between pa-
tients with single-chamber and dual-chamber ICD
was analyzed using Mann-Whitney U test for con-
tinuous variables and two-sided exact Fisher test
for categorical variables. P < 0.05 was considered
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statistically significant. All analyses were performed
using the Statistica 7.1 software.
Results
We studied 190 patients, including 36 women
and 154 men (mean age 57.2 ± 11.2 years, range
14–79 years) with ICD. Ischemic heart disease was
diagnosed in 146 patients, including 123 patients
with a history of myocardial infarction (more than
one previous infarct in 14 patients). Postinfarction
left ventricular aneurysm was found in 15 patients.
Coronary artery bypass grafting was previously
performed in 45 patients, and percutaneous coro-
nary angioplasty in 47 patients. Other primary car-
diac diagnoses included dilated cardiomyopathy in
22 patients, hypertrophic cardiomyopathy in 5 pa-
tients, long QT syndrome in 3 patients, arrhyth-
mogenic right ventricular cardiomyopathy in 2 pa-
tients, previous repair of the tetralogy of Fallot in
2 patients, previous correction of the transposition
of great arteries in one patient, and Brugada syn-
drome in one patient. No organic heart disease was
found in 8 patients.
Overall, the mean NYHA class at the time of
initial ICD insertion was 1.8 ± 0.7, and the study group
included 51 patients in NYHA class I, 117 patients in
NYHA class II, and 22 patients in NYHA class III. The
mean LVEF was 37 ± 14% (range 15–80%).
Sustained VT was the indication for ICD im-
plantation in 90 cases, and VF in 59 cases. In 29 pa-
tients, both types of ventricular arrhythmia were
documented, and ICD was used for primary preven-
tion in 12 patients.
Atrial flutter and/or fibrillation was present at
the time of ICD implantation in 46 (24.2%) patients.
LBBB was noted in 15 patients, and RBBB in 4 pa-
tients. Seven patients underwent previous pace-
maker implantation, including 5 patients due to sick
sinus syndrome, one patient due to atrial fibrilla-
tion with slow ventricular response, and one patient
due to advanced grade II atrioventricular block.
The mean duration of follow-up was 34.3 ±
± 22 months (range 17 days to 89 months). During
that time, patients were seen at on average 9.2 ±
± 5.6 (range 1–28) follow-up visits. Single-cham-
ber ICD was used in 136 patients, dual-chamber ICD
in 53 patients, and a combined ICD-cardiac resyn-
chronization therapy device was implanted in one pa-
tients. We used devices manufactured by three com-
panies: Biotronik (n = 115), Medtronic (n = 66), and
St. Jude Medical (n = 9).
Clinical events during the follow-up
During the follow-up, 55 patients underwent
device reimplantation, most commonly due to de-
pletion of battery power, but also due to capacitor
malfunction (resulting in prolonged device loading
time) in 11 patients. Later, 4 patients underwent
another device reimplantation, due to depletion of
battery power in three cases, and in one patient due
to exacerbation of heart failure that necessitated the
use of a combined ICD-cardiac resynchronization
device.
No ventricular arrhythmia event or inappropri-
ate ICD therapy was noted in 72 (37.5%) of 190 pa-
tients. No ventricular arrhythmia was also noted in
23 (12.1%) patients who experienced inappropriate
ICD therapy.
Overall, 2244 events occurred during the fol-
low-up, including both adequate and inadequate ICD
discharge. We found that 431 events (19.2%) could
be considered inappropriate ICD activation. Table 1
shows the rate and causes of inappropriate ICD dis-
charge. Most cases of inappropriate device activation
were due to atrial fibrillation or flutter, followed by
sinus tachycardia and oversensing of other signals
than T wave. The latter included detection of muscle
potential, R wave double counting, and far field sens-
ing, when ICD lead damage could be excluded.
Inappropriate arrhythmia detection was noted
in 64 (33.6%) patients, including 11 patients with
two different causes of inappropriate ICD discharge.
In terms of the number of affected patients, the
most common cause of inappropriate arrhythmia
detection and ICD discharge was sinus tachycardia,
followed by atrial fibrillation and oversensing of
other signals than T wave.
Comparison of single-chamber
and dual-chamber ICD
In our study group of 190 patients, single-cham-
ber ICD (ICD-VVI) was implanted in 136 (72%)
patients, and dual-chamber ICD (ICD-DDD) in
54 (28%) patients. The two groups did not differ sig-
nificantly in terms of any evaluated clinical param-
eter. The rate of inappropriate device therapy did
not depend on the type of ICD (i.e. single-chamber
versus dual chamber device). Inappropriate ICD
discharge was found in 20.4% of all cases of thera-
peutic device activation in patients with single-cham-
ber ICD, compared to 17.0% cases of device activa-
tion in patients with dual-chamber ICD (p = NS).
The most common cause of inappropriate ICD
discharge in patients with dual-chamber ICD both
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in terms of the number of events (n = 57) and the
number of patients (n = 8) was T wave oversens-
ing, followed by sinus tachycardia (7 patients and
9 events), atrial fibrillation (5 patients and
28 events), oversensing of other signals than
T wave (3 patients, 11 event), and slow VT and un-
sustained VT (1 event each).
Dual-chamber ICD implantation resulted in
less frequent inappropriate device therapy in cases
of atrial fibrillation and/or flutter and sinus tachy-
cardia compared to patients with single-chamber
ICD. Table 2 shows the rate and causes of inappro-
priate device therapy due to rapid supraventricular
rhythms depending on the type of ICD used (single-
-chamber versus dual chamber device).
Discussion
Since the initial successful ICD implantation in
1980, numerous clinical trials showed benefits of
ICD therapy in the prevention of sudden cardiac
death [7–14]. ICD implantation is indicated in pa-
tients who survived cardiac arrest due to VF or
hemodynamically unstable VT (unless the arrhyth-
mia resulted from a reversible cause), and in whom
further life expectancy exceeds one year in a good
clinical condition. For some years now, major chang-
es being introduced to the American and European
guidelines in terms of wider indications for ICD
implantation are mostly related to the primary pre-
vention of sudden cardiac death and include patients
at risk of life-threatening ventricular arrhythmia
(e.g. Brugada syndrome, long QT syndrome, vari-
ous cardiomyopathies), and patients with severely
depressed left ventricular systolic function follow-
ing a myocardial infarction, as manifested by low
LVEF [6].
However, ICD implantation is associated with
a range of problems. These include procedure-re-
lated complications (hematomas and surgical wound
infections, infections involving ICD itself, lead dis-
location or damage, and device damage) [22] and
complications related to ICD functioning (inappro-
priate device activation, electrical storm). Numer-
ous observations in patients with single-chamber
ICD showed inappropriate device activation in ap-
proximately 20 to 30% of patients. The most com-
mon cause of inappropriate arrhythmia detection
leading to inappropriate device discharge is su-
praventricular arrhythmia, and particularly atrial
fibrillation [23–28]. Thus, dual-chamber devices
that also use a signal from the atrial lead to recog-
nize the type of cardiac arrhythmia were suggest-
ed to result in better discrimination of ventricular
and supraventricular arrhythmia.
Benefits related to the use of dual-chamber
ICD devices were shown in the Atrial Sensing
To Reduce Inappropriate Defibrillation Study
(ASTRID). In this study, algorithms using atrial and
ventricular signal were associated with a reduced
Table 1. Rate and causes of inappropriate device dicharge in 190 patients with implanted cardioverter-
-defibrillator (ICD).
Causes of inappropriate ICD therapy* Number of inappropriate Number of
therapy events** patients***
Sinus tachycardia 66 (15.31%) 17 (27%)
Atrial fibrillation/flutter (AF/AFl) 182 (42.23%) 12 (22%)
Oversensing of other signals than T wave 66 (15.31%) 9 (14%)
T wave oversensing 61 (14.15%) 8 (12.5%)
Supraventricular tachycardia 2 (0.46%) 1 (1.5%)
Lead damage 40 (9.28%) 1 (1.5%)
Slow ventricular tachycardia (VT) 11 (2.56%) 5 (8%)
Unsustained VT 3 (0.7%) 0
Sinus tachycardia + other signal oversensing 4 (6%)
AF/AFl + slow VT 2 (3%)
AF/AFl + unsustained VT 2 (3%)
Sinus tachycardia + T wave oversensing 1 (1.5%)
Sinus tachycardia + lead damage 1 (1.5)
Unsustained VT + slow VT 1 (1.5%)
Overall 431 64
*Including the occurrence of two different causes of inappropriate ICD therapy in the same patient; **Percentage rate calculated for all inappropriate
ICD therapy events; ***Percentage rate calculated for all patients who experienced inappropriate ICD therapy
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number of inappropriate ICD discharge (0.04 ±
± 0.15 events/patient/month) compared to the devices
that only used the ventricular rate criterion (0.58 ±
± 4.23 events/patient/month, p = 0.0425) [29].
Supraventricular tachyarrrhythmias as the
major cause of inappropriate ICD discharge
The most common causes of inappropriate ICD
therapy include rapid supraventricular rhythms
such as sinus tachycardia, atrial fibrillation and flut-
ter, and supraventricular tachycardia.
In our study, sinus tachycardia was the cause
of inappropriate ICD therapy in the highest number
of patients with inappropriate arrhythmia detection,
as it was seen in 23 (36%) of 64 such patients. We
noted 66 inappropriate ICD therapy events due to
sinus tachycardia (about 15% of all such events).
Sinus tachycardia is usually related to exercise, but
it may also be associated with such clinical condi-
tions as anemia, hyperthyroidism, respiratory fail-
ure or heart failure. The management should be
directed at the treatment of the primary conditon,
and may include appropriate use of drugs, mainly
beta-blockers, to control the heart rate.
To avoid problems related to sinus tachycar-
dia in patients with ICD, some centers routinely
perform Holter monitoring and an exercise test
during the same hospitalization after the device
implantation. This allows objective confirmation of
the adequacy of VT recognition zone set during ICD
implantation. Such testing was not performed rou-
tinely in our center. Another way to prevent inade-
quate device therapy due to sinus tachycardia is the
use of appropriate additional diagnostic criteria of
ventricular arrhythmia, such as acute onset of ar-
rhythmia, EGM width, and EGM morphology. The
first of these criteria is based on the fact that the
onset of ventricular arrhythmia is usually acute,
whereas the heart rate increases more gradually in
cases of sinus tachycardia. Some clinical situations,
however, may render this algorithm inappropriate
and result in the lack of ICD therapy despite the
actual presence of ventricular arrhythmia (false-
-negative arrhythmia detection). For example, such
a situation might occur when VT is preceded by
a supraventricular arrhythmia, or VT cycle is ini-
tially longer than the VT recognition threshold set,
but later gradually decreases below this value.
The two other criteria are based on differences of
QRS width and morphology between supraventricular
and ventricular arrhythmia. Some centers do not pro-
gram these additional algorithms following ICD implan-
tation due to reports that their use increases the specif-
icity but decreases the sensitivity of VT recognition [30].Ta
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Instead, the acute onset of arrhythmia criterion is usu-
ally the only one that is initially programmed, and the
other additional algorithms are only switched on after
some events of inappropriate device therapy due to
sinus tachycardia are recorded.
Antiarrhythmic drug may slow the VT rate
below the maximum set rate of sinus tachycardia.
On the other hand, decreasing the lower rate
threshold of VT recognition may lead to an in-
creased risk of inappropriate device therapy due to
sinus tachycardia. The use of antiarrhythmic drugs
to suppress ventricular arrhythmia in the context
of inappropriate arrhythmia detection was discussed
by Paul et al. [31]. These authors examined the ef-
fect of antiarrhythmic drug treatment on the rate
of inappropriate ICD discharge. Among patients
treated with class Ia drugs, the rate of inappropri-
ate ICD discharge was 35% compared to 33%
among patients treated with amiodarone, 41%
among patients treated with class Ic drugs, and 63%
among patients who received various combinations
of antiarrhythmic drugs.
In a study by Królak et al. [32], sinus tachycar-
dia was the main cause of inappropriate rhythm
detection, noted in 227 (31%) of 725 events, while
in our study 15% of inappropriate ICD therapy
events were due to sinus tachycardia. This differ-
ence might have resulted from the fact that the ad-
ditional algorithms differentiating between su-
praventricular and ventricular arrhythmia (eg. the
acute onset of arrhythmia criterion) were not pro-
grammed initially but only after first episodes of
inappropriate device therapy. Schaumann et al. [33]
evaluated the efficacy of additional diagnostic algo-
rithms (acute onset of arrhythmia and rhythm sta-
bility criteria) in preventing inappropriate ICD ther-
apy due to sinus tachycardia and atrial fibrillation.
The study included 124 patients, and the mean du-
ration of follow-up was 20 months. Overall, inappro-
priate rhythm detection was noted in 13 (11%) pa-
tients, including two patients with inappropriate
ICD therapy due to sinus tachycardia (15% of all
patients with inappropriate rhythm detection).
In our study, the most common cause of inap-
propriate ICD therapy in terms of number of events
was atrial fibrillation and/or flutter. These data are
in agreement with most studies regarding inappro-
priate ICD therapy in which such a cause was iden-
tified in approximately 20% of all events.
In a study of 86 patients followed for 17 ± 9 mon-
ths by Schmidt et al. [24], atrial fibrillation and/or
flutter was the most common cause of inappropri-
ate rhythm detection, noted in about 13% of pa-
tients. O’Nunain et al. [27] reported inappropriate
ICD therapy due to atrial fibrillation and/or flutter
in 21% of patients. Królak et al. [32] found that atrial
fibrillation was the cause of 156 (5.6%) episodes of
inappropriate rhythm detection and device activation,
occurring in 14 (7.2%) patients. Rinaldi et al. [34]
summarized 17 years of their experience with ICD
and found inappropriate device therapy in 22 (14%)
of 171 patients, with atrial fibrillation and sinus tachy-
cardia being the most common causes (noted in 18 pa-
tients).
Did the introduction of dual-chamber ICD
reduced the rate of inappropriate therapy
due to rapid supraventricular rhythms?
As noted above, reducing the rate of inappro-
priate device therapy was the main rationale for
introducing dual-chamber ICD.
In this regard, no conclusive data were obtained
in a small group of patients (n = 21) reported by
Fan et al. [35]. Similar results were presented by
Hugl et al. [36].
In our study, dual-chamber ICD was implant-
ed in 54 (28%) of 190 patients, and inappropriate
device therapy was noted in 21 (38%) of these pa-
tients. The most common causes were T wave
sensing, sinus tachycardia and atrial fibrillation,
occurring with a similar rate compared to patients
with single chamber ICD. However, the use of dual-
-chamber ICD resulted in better discrimination of
rapid supraventricular rhythms and reduced
number of patients with inappropriate device thera-
py due to atrial fibrillation and/or flutter and sinus
tachycardia. Of note, patients in our study group
were treated with various ICD models by different
manufacturers, using various advanced algorithms
to distinguish between supraventricular and ven-
tricular arrhythmia, such as PR Logic (Medtronic),
Smart (Biotronik), and AV Rate Branch (St. Jude
Medical). Thus, our results may not necessarily
apply to particular models of dual-chamber ICD. No
difference in the number of patients with inappro-
priate device therapy due to supraventricular ar-
rhythmia between groups with single-chamber and
dual-chamber ICD, albeit with smaller number of
such episodes in patients with dual-chamber ICD,
may be explained by the the fact that additional al-
gorithms to distinguish between supraventricular
and ventricular arrhythmia were switched on only
after the first event of inappropriate rhythm detec-
tion was recorded. Thus, only the number of events
but not the number of patients with this problem
could have been affected.
In contrast, Deisenhofer et al. [37] were not
able to show benefits from the use of dual-chamber
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devices in a group of 92 patients (including 45 pa-
tients with single-chamber ICD and 47 patients with
dual-chamber ICD) in terms of reduced rate of in-
appropriate device therapy due to rapid supraven-
tricular rhythms. The authors reported that most
problems with inappropriate rhythm detection us-
ing additional diagnostic algorithms were related to
atrial sensing malfunction (38 of 51 inappropriate
therapy events).
Hintriger et al. [38] compared diagnostic algo-
rithms used by various manufacturers to distinguish
between supraventricular and ventricular arrhyth-
mia during the electrophysiological study. None of
the algorithms evaluated was shown to be 100%
specific in detecting supraventricular arrhythmia.
The devices proved to be most efficient at recogni-
tion of atrial fibrillation but fared worse in terms of
detecting other rapid supraventricular rhythms (sinus
tachycardia, atrioventricular nodal reentrant tachy-
cardia etc.). The best results were obtained for
GEM DR 7271 (Medtronic) and Defender IV (ELA)
devices, while problems with detecting rapid
rhythms resulting in stable ventricular rate were
seen in case of Phylax AV (Biotronik) and Ventak
AV III DR (Guidant) devices. The algorithms used
by Medtronic and ELA devices are based on the
analysis of PR intervals, sudden onset of arrhyth-
mia and the ratio of atrial to ventricular impulses.
Better results in terms of detection of supraven-
tricular arrhythmia (specificity up to 89%) were
reported by Kouakam et al. [39] who tested the
usefulness of the Atrial View algorithm used in
Guidant devices.
In summary, both our findings and data from
the literature suggest that fast atrial rhythms con-
tinue to be the major cause of inappropriate ICD
therapy that could not be eliminated despite signif-
icant technological advances in this area.
Conclusions
1. Inappropriate arrhythmia detection leading to
inappropriate device discharge remains a ma-
jor clinical problem in patients with implanted
cardioverter-defibrillator.
2. The most common causes of erroneous rhythm
detection and inappropriate therapeutic ICD
discharge are sinus tachycardia and atrial fibril-
lation and/or flutter.
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